EnteroMedics

About:

EnteroMedics® Inc. (NASDAQ: ETRM) is the developer of in-class weight loss treatments for obesity and obesity related risk factors.

Website: http://enteromedics.com

Top Investors: MPM Capital, Aberdare Ventures, Bay City Capital

Description:

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

Total Funding Amount:

$161M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Saint Paul, Minnesota, United States

Founded Date:

2002-01-01

Contact Email:

info(AT)enteromedics.com

Founders:

Mark B. Knudson

Number of Employees:

11-50

Last Funding Date:

2017-10-18

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai